BiotechTube

eteplirsen

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Duchenne Muscular Dystrophy (DMD)

Conditions

Duchenne Muscular Dystrophy (DMD)

Trial Timeline

Nov 17, 2014 → Jun 14, 2019

NCT ID
NCT02255552

About eteplirsen

eteplirsen is a phase 3 stage product being developed by Sarepta Therapeutics for Duchenne Muscular Dystrophy (DMD). The current trial status is completed. This product is registered under clinical trial identifier NCT02255552. Target conditions include Duchenne Muscular Dystrophy (DMD).

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (6)

NCT IDPhaseStatus
NCT03992430Phase 3Active
NCT03985878Phase 2Terminated
NCT03218995Phase 2Completed
NCT02420379Phase 2Completed
NCT02255552Phase 3Completed
NCT02286947Phase 2Completed

Competing Products

20 competing products in Duchenne Muscular Dystrophy (DMD)

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
33
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
33
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
33
Tadalafil + PlaceboEli LillyPhase 3
77
DS-5141bDaiichi SankyoPhase 2
52
DS-5141bDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
41
NS-065/NCNP-01Nippon ShinyakuPhase 2
52
Viltolarsen + PlaceboNippon ShinyakuPhase 3
77
ViltolarsenNippon ShinyakuPhase 2
52
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
52
NS-065/NCNP-01Nippon ShinyakuPhase 1
33
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
41
NS-089/NCNP-02Nippon ShinyakuPhase 2
52
ViltolarsenNippon ShinyakuPhase 3
77
NS-089/NCNP-02Nippon ShinyakuPhase 1/2
41
NS-065/NCNP-01 + PlaceboNippon ShinyakuPhase 2
52
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wkMerckPhase 2
52
ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)MerckPhase 2
52

Other Products from Sarepta Therapeutics

Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]Approved
80
EteplirsenPhase 3
72
SRP-9005 + CorticosteroidPhase 3
72
Casimersen + GolodirsenPhase 3
72
SRP-9003 + GlucocorticoidPhase 3
72